Cystic fibrosis medicine Kalydeco now available in New Zealand

26 February 2020

US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that Kalydeco (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1. Clinicians are able to apply for patient access using the exceptional circumstances framework set up by the Pharmaceutical Management Agency (PHARMAC).

According to a PHARMAC statement, Kalydeco will be listed in Section B (as PCT only) and Section H of the Pharmaceutical Schedule, at a date to be determined following Medsafe approval, at the following price (ex-manufacturer, excluding GST):

Chemical	Formulation	Brand	Pack size	Proposed price and subsidy
Ivacaftor	Tab 150mg	Kalydeco	56	NZ$29,386.00
Ivacaftor	Grans 50mg, sachet	Kalydeco	56	NZ$29,386.00
Ivacaftor	Grans 75mg, sachet	Kalydeco	56	NZ$29,386.00

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK